Table 2.
Main ongoing clinical trials in oligoprogressive NSCLC.
| Trial | Active Comparator Arm | Experimental Arm |
Tumor Type | Molecular Selection | Definition of Oligroprogression | Primary Endpoint | Phase | Status |
|---|---|---|---|---|---|---|---|---|
|
NCT02756793 (STOP trial) |
SoC (Continue with current systemic agent(s)/Observation/Switch to next-line treatment | SABR + continuation of current systemic agents | NSCLC | - | Maximum of 3 progressing metastases in any single organ system and the total number of metastases must be 5 or less | PFS | - | Active, not recruiting |
| NCT04519983 | - | Upfront TKI + Salvage SRT | NSCLC | EGFR | Intracranial oligo-progression | iORR | 2 | Not yet recruiting |
| NCT04405401 (SUPPRESS-NSCLC) | SoC (Switch to subsequent systemic therapy line/BSC/continue current systemic line) | SABR to oligoprogressive lesions + continue current systemic therapy | NSCLC | - | 1–5 extracranial lesions | PFS, OS | 2 | Recruiting |
| NCT03256981 (HALT) | Continued TKI therapy alone | SBRT and continued TKI therapy | NSCLC | actionable mutation treated with TKI | ≤3 extracranial sites of progressive disease | PFS | 2/3 | Recruiting |
| NCT03808662 | SoC | SBRT | NSCLC, breast cancer | Non oncogene-addicted cohort + oncogene-addicted cohort | 1–5 oligo-progressive lesions | PFS | 2 | Recruiting |
SoC: standard of care, NSCLC: non-small cell lung cancer, PFS: progression-free survival, iORR: intracranial objective response rate; BSC: best supportive care; OS: overall survival.